Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 83 of 151

  1. MEDI8968 600 mg IV, 300 mg SC

    MedImmune

    Chronic Obstructive Pulmonary Disease

    phase 2 mab completed

    1 trial

  2. MEDI9929

    MedImmune

    Atopic Dermatitis

    phase 2 mab completed

    1 trial

  3. MELISSA

    Fondazione Telethon ETS

    Relapsed Multiple Myeloma

    phase 2 small molecule active

    1 trial

  4. MEPENDAX

    ISTA Pharma Limited

    Ependymoma, Medulloblastoma

    phase 2 small molecule active

    1 trial

  5. METFORAL 850 mg compresse rivestite con film

    Fondazione Telethon ETS

    Triple negative breast cancer

    phase 2 small molecule active

    1 trial

  6. METFORMIN

    Istituto Gentili S.r.l.

    bone sarcoma

    phase 2 small molecule active

    1 trial

  7. METFORMIN , Placebo 515

    Pari Pharma GmbH

    Portal hypertension (PHT) and consequences in complications of cirrhosis

    phase 2 small molecule active

    1 trial

  8. METRONIDAZOLE for Pouchitis

    Lacuna Pharma Pty Ltd

    Pouchitis

    phase 2 small molecule active

    1 trial

  9. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    Non-alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  10. MGL-3196 (resmetirom)

    Madrigal Pharmaceuticals EU Limited

    Heterozygous Familial Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  11. MHS-1031

    CATALYST PHARMACEUTICALS, INC.

    Gastroesophageal Reflux

    phase 2 small molecule active

    1 trial

  12. MI-CBT

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol Abuse

    phase 2 other completed

    1 trial

  13. MI/CBT

    BRIGHT MINDS BIOSCIENCES INC.

    Alcoholic, Marijuana Misuse

    phase 2 other completed

    1 trial

  14. MIA2019/CT/258

    The George Institute

    melanoma brain metastases

    phase 2 small molecule active

    1 trial

  15. MIBIOTIMI

    The George Institute

    Breast cancer

    phase 2 other active

    1 trial

  16. MIE

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 other active

    1 trial

  17. MINOCIN 100 mg capsule rigide

    Zafatek

    Depression

    phase 2 small molecule active

    1 trial

  18. MITAPIVAT

    Lacuna Pharma Pty Ltd

    Sickle Cell Disease (SCD) and Nephropathy

    phase 2 small molecule active

    1 trial

  19. MITO 25.1

    Fondazione Telethon ETS

    Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer.

    phase 2 small molecule active

    1 trial

  20. MITO 35a

    Fondazione Telethon ETS

    BRCA wild-type advanced ovarian, fallopian tube and primitive peritoneal cancer

    phase 2 small molecule active

    1 trial

  21. MITO VULVA-01

    Fondazione Telethon ETS

    vulvar cancer

    phase 2 small molecule active

    1 trial

  22. MK-1022-010

    Merck Sharp and Dohme

    High Risk Early-Stage Triple Negative Breast Cancer (TNBC) or Hormone Receptor Low Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR-low+/HER2-) Breast Cancer

    phase 2 small molecule active

    1 trial

  23. MK-1022-011

    Merck Sharp and Dohme

    Colorectal Carcinoma, Biliary Tract Carcinoma, Hepatocellular Carcinoma​

    phase 2 small molecule active

    1 trial

  24. MK-1026-003

    Merck Sharp and Dohme

    Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters transformation; Mantle cell lymphoma, Marginal zone lymphoma; Follicular lymphoma; Waldenström’s macroglobulinemia

    phase 2 small molecule active

    1 trial

  25. MK-1045

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  26. MK-1084-014

    Merck Sharp and Dohme

    Neoplasm malignant with KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  27. MK-1167

    Merck KGaA, Darmstadt, Germany

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  28. MK-1167-008

    Merck Sharp and Dohme

    Alzheimer’s disease dementia

    phase 2 small molecule active

    1 trial

  29. MK-1200-002

    Merck Sharp and Dohme

    Advanced solid tumor

    phase 2 small molecule active

    1 trial

  30. MK-2060, Placebo to MK-2060

    Merck Sharp and Dohme

    Prevention of arteriovenous graft thrombosis

    phase 2 small molecule active

    1 trial

  31. MK-2140-006

    Merck Sharp and Dohme

    Aggressive and Indolent B-cell Malignancies (mantle cell lymphoma; chronic lymphocytic leukemia; follicular lymphoma; Richter’s syndrome)

    phase 2 small molecule active

    1 trial

  32. MK-2140-011

    Merck Sharp and Dohme

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  33. MK-2214

    Merck KGaA, Darmstadt, Germany

    Early Alzheimer's Disease

    phase 2 mab active

    1 trial

  34. MK-2214-004

    Merck Sharp and Dohme

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  35. MK-2400-01A

    Merck Sharp and Dohme

    Metastatic castrate resistant prostate cancer - mCRPC

    phase 2 small molecule active

    1 trial

  36. MK-2870-027

    Merck Sharp and Dohme

    Intermediate-risk Non-muscle Invasive Bladder Cancer

    phase 2 other active

    1 trial

  37. MK-3120

    Merck Sharp and Dohme

    Advanced/metastatic solid tumor disease

    phase 2 small molecule active

    1 trial

  38. MK-3120

    Merck Sharp and Dohme

    High-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors

    phase 2 small molecule active

    1 trial

  39. MK-3475-01A

    Merck Sharp and Dohme

    non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  40. MK-3475-01B

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  41. MK-3475-01C

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  42. MK-3475-01E

    Merck Sharp and Dohme

    Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  43. MK-3475-01F

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  44. MK-3475-01H

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  45. MK-3475-01I

    Merck Sharp and Dohme

    Stage IV Squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  46. MK-3475-01J

    Merck Sharp and Dohme

    Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC

    phase 2 small molecule active

    1 trial

  47. MK-3475-02A

    Merck Sharp and Dohme

    PD-1 refractory melanoma

    phase 2 small molecule active

    1 trial

  48. MK-3475-02B

    Merck Sharp and Dohme

    PD-1 refractory melanoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.